Empagliflozin may protect the heart by altering the expression of genes including Apoe, Apoc1, Saa2, Apoa2, and Pon1, which are all involved in lipid metabolism disturbance in obesity. Here, PON1 is linked to obesity due to melanocortin 4 receptor deficiency.